Thiago Favano, Senior Director at MiNK Therapeutics, shared on LinkedIn:
“Great to be at IGCS2026 in Montréal, where Dr. Rebecca Porter (Dana – Farber Cancer Institute) presented 3 – year overall survival data from the recurrent ovarian cancer cohort of the Phase 1b C – 800 – 01 study of botensilimab plus balstilimab.
The session drew a full room and great engagement from the gynecologic oncology community. That’s a reminder of how much need remains in recurrent ovarian cancer, especially platinum – resistant disease.
Thank you to Dr. Porter, the investigators, and above all the patients and families who made this research possible.”
Other articles featuring Thiago Favano on OncoDaily.
